> RUN 04 / FAQ / 29 QUESTIONS / RESEARCH-SOURCED ANSWERS
Sermorelin: Frequently Asked Questions
29 questions on Sermorelin — mechanism, dosage, side effects, regulatory status, and comparisons — answered from peer-reviewed clinical trial literature.
How does sermorelin work?
Sermorelin binds GHRH receptors on pituitary somatotroph cells, activating adenylyl cyclase and triggering pulsatile GH secretion via a cAMP → PKA → Ca²⁺ cascade [9]. The somatostatin negative-feedback loop stays intact, so GH elevation is episodic rather than continuous. The pituitary releases its own GH — sermorelin does not introduce exogenous GH.
What does Sermorelin do to the body?
Sermorelin triggers pulsatile GH secretion from the anterior pituitary. GH then stimulates hepatic IGF-1 synthesis. Downstream effects documented in clinical trials include lean mass increase, fat mass decrease, improved nocturnal sleep architecture, and improved cognitive performance in GH-declining adult cohorts [6][7][8]. Effects are mediated through the GH → IGF-1 axis.
Is sermorelin a peptide?
Yes. Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of endogenous GHRH. It is the shortest GHRH fragment that retains full GHRH-receptor binding affinity and GH-stimulating activity. Molecular weight: 3358 Da. CAS: 86168-78-7.
Is sermorelin a steroid?
No. Sermorelin is a 29-amino-acid peptide — not a steroid. Steroids are cholesterol-derived with a four-ring carbon skeleton; peptides are short amino acid chains. They differ in structure, receptor target, mechanism of action, and regulatory classification.
What is sermorelin acetate?
Sermorelin acetate is the acetate salt of GHRH(1-29)-NH2 — the form used in the original Geref preparation. The acetate counterion aids aqueous solubility and lyophilization stability. Supplied as lyophilized white powder for subcutaneous injection after reconstitution with bacteriostatic or sterile water.
What is sermorelin used for?
Originally FDA-approved for pediatric growth hormone deficiency (1997–2009). Subsequent research studied sermorelin for adult GH-axis decline, body composition modulation in GH-declining elderly adults, sleep architecture improvement, and cognitive function [1][6][7][8]. Available now via compounding pharmacies as a prescription compound.
Does sermorelin work?
Yes, in the populations studied. GH elevation: documented in every human pharmacodynamic study [3][5]. IGF-1 elevation: 35–40% at 6 months in elderly adults [6]. Body composition: lean mass up, fat mass down at 6 months in elderly adults [6]. Cognitive performance: executive function and processing speed improved in 89 older adults [7]. Pediatric height velocity: 4.1 → 8.0 cm/yr at 6 months [1].
How long does it take for sermorelin to work?
Acute GH pulse: detectable 30–60 minutes post-injection [3]. IGF-1 changes: within weeks; statistically significant at 6 weeks in Vittone et al. [5]. Body composition shifts: 3–6 months in published adult trial timelines [6]. Height velocity: significant improvement documented at the 6-month measurement in pediatric GHD trials [1].
Does sermorelin help with weight loss?
Clinical data support visceral fat reduction in GH-declining adults at 6 months — approximately 5% body fat decrease in the Merriam 2011 program [6]. The GHRH-analog tesamorelin produced −35 cm² visceral adipose tissue reduction versus placebo over 12 months [10]. These are body composition endpoints in specific populations — not generalized weight loss data.
Does sermorelin build muscle?
Lean body mass increased in Merriam et al.'s 6-month elderly adult study [6]. The GH → IGF-1 pathway drives anabolic signaling in skeletal muscle. A combination GH secretagogue protocol (sermorelin + GHRP-6 + GHRP-2) raised IGF-1 from 159.5 to 239.0 ng/mL in 105 hypogonadal men [12]. Muscle effects in healthy eugonadal adults with normal GH are not well characterized.
Does sermorelin increase testosterone?
No direct controlled evidence that sermorelin raises testosterone. GH/IGF-1 may indirectly influence Leydig cell steroidogenesis, but the relationship in humans is poorly characterized. Sigalos et al. (2017) reported IGF-1 elevation — not testosterone — as the primary outcome in hypogonadal men [12]. Controlled RCT data are absent.
Is 3 months of sermorelin enough?
Published trials suggest variable timelines. Acute GH pulse is immediate; IGF-1 rises within weeks. In the Merriam 2011 program, body composition shifts were measured at 6 months [6]. Some studies observed meaningful IGF-1 improvement before 6 months, but no published trial specifically used a 3-month endpoint as its primary body-composition terminus for adult populations.
Has anyone noticed better sleep on Sermorelin?
Sleep improvement was documented in elderly subjects receiving pulsatile nocturnal GHRH: reduced nocturnal awakenings and extended first NREM sleep period [8]. GH secretion was activated in approximately 70% of elderly subjects (versus near 100% in younger subjects), with substantially attenuated effects in the older cohort [8].
How much sermorelin per day?
Pediatric GHD trials: 30 mcg/kg/day subcutaneous [1]. Adult elderly studies: approximately 1–2 mg subcutaneous nightly [5][6]. Combination secretagogue protocol: 100 mcg subcutaneous three times daily [12]. These are doses from specific research protocols — not prescribing guidance.
When is the best time to take sermorelin?
Published research protocols specify pre-sleep administration: the dominant nocturnal GH pulse coincides with slow-wave sleep onset, somatostatin tone is lowest at sleep onset, and pre-sleep fasting minimizes food-stimulated insulin interference with GH release [6]. The Geref prescribing information specified subcutaneous administration at bedtime.
Where to inject sermorelin?
Subcutaneous injection. Published protocols and the Geref prescribing information specified subcutaneous administration at the abdomen or thigh. Intravenous route was used only for pharmacokinetic characterization and acute stimulation testing in research settings [3][4]. Intranasal bioavailability is only 3–5% — not viable [3].
Does sermorelin need to be refrigerated?
Lyophilized (freeze-dried) sermorelin powder is stable at room temperature in sealed vials. Reconstituted peptide solution requires refrigeration. Study protocols specify use within the period defined in the product's protocol — typically 7–14 days per standard compounding pharmacy labeling conventions.
Is sermorelin FDA approved?
Yes — historically, for pediatric GHD. Sermorelin (Geref, NDA 20-443) received FDA approval on September 26, 1997 for treatment of idiopathic GH deficiency in children with growth failure [15]. The manufacturer (EMD Serono) voluntarily withdrew the product in 2008–2009. The FDA's 2013 determination confirmed the withdrawal was not for safety or efficacy reasons [15]. Sermorelin is now available via 503A/503B compounding pharmacies.
Is sermorelin legal?
Sermorelin occupies a distinct regulatory space from unapproved research chemicals — it is a formerly FDA-approved compound now available as a compounded prescription medication in the U.S. under Section 503A/503B [15]. It is not a controlled substance under the DEA Controlled Substances Act. It is prohibited in competitive sport under WADA S2 [16].
Why is Sermorelin banned in sports?
WADA prohibits sermorelin under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) because it stimulates endogenous GH production [16]. GH is itself prohibited at supraphysiologic concentrations. Stimulating GH via GHRH analogs is therefore prohibited as an indirect performance-enhancement pathway — the prohibition is categorical at any dose.
Does sermorelin show up on a drug test?
WADA-certified laboratories can detect sermorelin via targeted LC-MS/MS urine methods at ≤0.5 ng/mL LOD [20]. After subcutaneous injection of 500 mcg, intact sermorelin is undetectable in plasma; the primary metabolite GRF3-29 is detectable from approximately 30 to 90 minutes post-injection [17]. Detection window is limited relative to many prohibited compounds, but validated WADA anti-doping methods exist [16].
What is safer, sermorelin or HGH?
Mechanistically, sermorelin preserves pituitary feedback regulation — endogenous somatostatin gates GH output, preventing supraphysiologic accumulation. Exogenous rhGH bypasses this gate and suppresses endogenous pituitary GH production. No head-to-head RCT comparing adult safety profiles has been published [19]. The mechanistic argument favors sermorelin's indirect mechanism; direct comparative safety evidence is absent.
sermorelin vs ipamorelin
Sermorelin acts on pituitary GHRH-R via the cAMP/PKA/Ca²⁺ cascade. Ipamorelin acts on the ghrelin receptor (GHS-R1a) via the phospholipase C/IP3/diacylglycerol pathway — a distinct intracellular route. When co-administered, the two classes act synergistically: GHRH alone +20-fold GH; GHRP-2 alone +47-fold; combination +54-fold [18]. Ipamorelin is noted for high GHS-R1a selectivity with minimal cortisol or prolactin elevation versus older GHRP compounds.
What pairs well with sermorelin?
The research supports GHRH + GHRP co-administration for synergistic GH pulse amplitude amplification [18]. Sigalos et al. (2017) published a sermorelin + GHRP-6 + GHRP-2 combination protocol in 105 hypogonadal men — IGF-1 rose from 159.5 to 239.0 ng/mL (p<0.0001) over 134 days [12]. These are research protocol findings — not prescribing guidance.
Is sermorelin better than GLP-1?
Sermorelin targets the somatotropic axis (pituitary GHRH-R); GLP-1 receptor agonists target the incretin axis (pancreatic, gut, and CNS GLP-1R). They address different physiological systems for different endpoints. No published comparison exists. They are mechanistically non-comparable compounds.
What are the downsides of Sermorelin?
Documented adverse events in clinical trials: injection-site reactions (most common), headache, flushing, dizziness, and nausea. Edema noted in some subjects — consistent with GH-axis activation and IGF-1-mediated renal sodium retention. Long-term tolerability data in adults are sparse; no large-scale post-market surveillance exists for compounded adult use [19].
What not to mix with Sermorelin?
Mechanistic interactions from the research literature: glucocorticoids (blunt GHRH-R expression and GH pulse amplitude); somatostatin analogs like octreotide (direct pharmacodynamic antagonist to GHRH-mediated GH release); estrogen replacement therapy (attenuates IGF-1 response to less than 10% versus approximately 40% in non-ERT subjects) [6]; high insulin states (blunt GH pulse — the basis for pre-sleep fasted administration).
Who should not use Sermorelin?
Published research protocol exclusion criteria: active malignancy (GH/IGF-1 have proliferative roles — universal exclusion in GH-axis trials); untreated hypothyroidism (impairs GH-axis responsiveness); hypopituitarism of non-GH origin; pregnancy (excluded from early trials). These are protocol exclusion criteria — not derived from an approved adult prescribing label, which does not exist.
Are there long-term side effects of Sermorelin?
Long-term adult data are sparse. The pediatric GHD program showed acceptable tolerability over multi-year use in children [15]. Adult trials have not exceeded 12 months. Theoretical long-term concerns: neoplasm stimulation (standard GH-axis concern), fluid retention, and glucose metabolism effects with sustained GH elevation. No specific long-term adverse effect pattern has been documented in published adult trials.
Can women take sermorelin?
Clinical trials enrolled both male and female subjects. Women on estrogen replacement therapy showed a substantially attenuated IGF-1 response — less than 10% increase versus approximately 40% in non-ERT women and men [6]. Women not on ERT showed IGF-1 responses comparable to men. GH secretion dynamics differ by sex; women have higher baseline GH pulse frequency at younger ages.
What does sermorelin do for men?
In elderly men specifically: Vittone et al. (1997) documented increased nocturnal GH peak amplitude and area under the curve at 2 mg nightly over 6 weeks [5]. Merriam et al. (2011) documented 35–40% IGF-1 increase, lean mass increase, and fat mass decrease at 6 months (~1 mg nightly) [6]. Sigalos et al. (2017) documented IGF-1 elevation from 159.5 to 239.0 ng/mL in hypogonadal men using combination GHRH + GHRP protocols [12].
Sermorelin Detectability in Anti-Doping Testing
WADA-certified anti-doping laboratories can detect sermorelin via targeted LC-MS/MS and nano-LC-Q/Orbitrap MS methods in urine at ≤0.5 ng/mL LOD [20]. The detection challenge: intact sermorelin clears from plasma within minutes; the primary urinary metabolite has a limited post-injection window. Validated methods exist for urine [16][20].
Sermorelin Research in Female Subjects
Both male and female subjects were enrolled in key adult sermorelin trials. The key finding in women: estrogen replacement therapy attenuated the IGF-1 response to less than 10% versus approximately 40% in non-ERT women [6]. Merriam et al. (2011) noted this as a clinically significant factor in the adult female population. Non-ERT women appear to respond similarly to men in terms of IGF-1 elevation.
Sermorelin Research Outcomes in Male Subjects
Male-specific outcomes from clinical trials: nocturnal GH amplitude increase (Vittone 1997) [5]; 35–40% IGF-1 increase, lean mass gain, fat mass reduction (Merriam 2011) [6]; IGF-1 elevation from 159.5 to 239.0 ng/mL in hypogonadal men using combination GH secretagogue protocol including sermorelin (Sigalos 2017) [12]. Cognitive improvements in the 6-month Vitiello 2006 cohort included both sexes [7].